Name in SEC filings: RECURSION PHARMACEUTICALS, INC.
Source: ORION, orionbiotechai.com/company/RXRX, data as of Oct 13, 2026
https://www.orionbiotechai.com/company/RXRX
REC-1245 · Topline/data readout · 2H26
SEC sources last checked .
○ Quote matched to filing (not yet reviewed by founder) · ✓ Checked by founder.
Topline/data readout2H26
Stage: Phase 1SEC filing · “Phase 1”
Public float: $2,030,000,000 · as of · SEC filing
REC-1245 (RBM39): Additional Phase 1 dose escalation data expected in 2H26
10-Q · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2026-12)
Topline/data readout1H27
Stage: Phase 1SEC filing · “Phase 1”
Public float: $2,030,000,000 · as of · SEC filing
REC-3565 (MALT1): Early Phase 1 safety and PK monotherapy data expected in 1H27
10-Q · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2027-06)
Topline/data readout1H27
Stage: OtherSEC filing · “Phase 1b/2”
Public float: $2,030,000,000 · as of · SEC filing
Additional Phase 1b/2 clinical data expected in 1H27
10-Q · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2027-06)
Topline/data readout1H27
Stage: Phase 1SEC filing · “Phase 1”
Public float: $2,030,000,000 · as of · SEC filing
REC-617 (CDK7): Early Phase 1 safety and PK combination data expected in 1H27
10-Q · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2027-06)
Topline/data readout2H27
Stage: Phase 1SEC filing · “Phase 1”
Public float: $2,030,000,000 · as of · SEC filing
REC-4539 (LSD1): Early Phase 1 safety and PK monotherapy data expected in 2H27
10-Q · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2027-12)
Company periods and sentences are quoted as written. A matching disclosure uses the SEC filing date for the same program and event type. As of .
| Program / event | Stated period and SEC wording | Disclosure in stated period |
|---|---|---|
| REC-1245Clinical results | 2H26“REC-1245 (RBM39): Additional Phase 1 dose escalation data expected in 2H26” Filed · 10-Q | Still within period As of Oct 19, 2026 |
| REC-3565Clinical results | 1H27“REC-3565 (MALT1): Early Phase 1 safety and PK monotherapy data expected in 1H27” Filed · 10-Q | Period not started The stated period has not started yet, so there is nothing to compare. |
| REC-4539Clinical results | 2H27“REC-4539 (LSD1): Early Phase 1 safety and PK monotherapy data expected in 2H27” Filed · 10-Q | Period not started The stated period has not started yet, so there is nothing to compare. |
| REC-617Clinical results | 1H27“REC-617 (CDK7): Early Phase 1 safety and PK combination data expected in 1H27” Filed · 10-Q | Period not started The stated period has not started yet, so there is nothing to compare. |
| REC-1245Clinical results | 2H26“REC-1245 (RBM39): Additional Phase 1 dose escalation data expected in 2H26” Filed · 10-Q | Still within period As of Oct 19, 2026 |
| REC-1245Clinical results | 2H26“REC-1245 (RBM39): Additional Phase 1 dose escalation data expected in 2H26” Filed · EX-99.1 | Still within period As of Oct 19, 2026 |
| REC-3565Clinical results | 1H27“REC-3565 (MALT1): Early Phase 1 safety and PK monotherapy data expected in 1H27” Filed · 10-Q | Period not started The stated period has not started yet, so there is nothing to compare. |
| REC-3565Clinical results | 1H27“REC-3565 (MALT1): Early Phase 1 safety and PK monotherapy data expected in 1H27” Filed · EX-99.1 | Period not started The stated period has not started yet, so there is nothing to compare. |
| REC-4539Clinical results | 2H27“REC-4539 (LSD1): Early Phase 1 safety and PK monotherapy data expected in 2H27” Filed · 10-Q | Period not started The stated period has not started yet, so there is nothing to compare. |
| REC-4539Clinical results | 2H27“REC-4539 (LSD1): Early Phase 1 safety and PK monotherapy data expected in 2H27” Filed · EX-99.1 | Period not started The stated period has not started yet, so there is nothing to compare. |
| REC-4881Clinical results | 1H27“Additional Phase 1b/2 clinical data expected in 1H27” Filed · 10-Q | Period not started The stated period has not started yet, so there is nothing to compare. |
| REC-617Clinical results | 1H27“REC-617 (CDK7): Early Phase 1 safety and PK combination data expected in 1H27” Filed · 10-Q | Period not started The stated period has not started yet, so there is nothing to compare. |
| REC-617Clinical results | 1H27“REC-617 (CDK7): Early Phase 1 safety and PK combination data expected in 1H27” Filed · EX-99.1 | Period not started The stated period has not started yet, so there is nothing to compare. |
| REC-3565Clinical results | 1H27“REC-3565 (MALT1): Early Phase 1 safety and PK monotherapy data expected in 1H27” Filed · 10-K | Period not started The stated period has not started yet, so there is nothing to compare. |
| REC-3565Clinical results | 1H27“REC-3565 (MALT1): Early Phase 1 safety and PK monotherapy data expected in 1H27” Filed · EX-99.1 | Period not started The stated period has not started yet, so there is nothing to compare. |
| REC-4539Clinical results | 2H27“REC-4539 (LSD1): Early Phase 1 safety and PK monotherapy data expected in 2H27” Filed · 10-K | Period not started The stated period has not started yet, so there is nothing to compare. |
| REC-4539Clinical results | 2H27“REC-4539 (LSD1): Early Phase 1 safety and PK monotherapy data expected in 2H27” Filed · EX-99.1 | Period not started The stated period has not started yet, so there is nothing to compare. |
| REC-617Clinical results | 1H27“REC-617 (CDK7): Early Phase 1 safety and PK combination data expected in 1H27” Filed · 10-K | Period not started The stated period has not started yet, so there is nothing to compare. |
| REC-617Clinical results | 1H27“REC-617 (CDK7): Early Phase 1 safety and PK combination data expected in 1H27” Filed · EX-99.1 | Period not started The stated period has not started yet, so there is nothing to compare. |
| REC-3565Clinical results | 1H27“REC-3565 (MALT1): Early Phase 1 safety and PK monotherapy data expected in 1H27” Filed · 10-Q | Period not started The stated period has not started yet, so there is nothing to compare. |
| REC-3565Clinical results | 1H27“REC-3565 (MALT1): Early Phase 1 safety and PK monotherapy data expected in 1H27” Filed · EX-99.1 | Period not started The stated period has not started yet, so there is nothing to compare. |
| REC-3565Clinical results | 2H26“REC-3565 (MALT1): Early Phase 1 safety and PK monotherapy data expected in 2H26” Filed · 10-Q | Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings. |
| REC-3565Clinical results | 2H26“REC-3565 (MALT1): Early Phase 1 safety and PK monotherapy data expected in 2H26” Filed · EX-99.1 | Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings. |
| REC-3565Clinical results | 2H26“REC-3565 (MALT1): Early Phase 1 safety and PK monotherapy data expected in 2H26” Filed · 10-Q | Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings. |
| REC-3565Clinical results | 2H26“REC-3565 (MALT1): Early Phase 1 safety and PK monotherapy data expected in 2H26” Filed · EX-99.1 | Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings. |
“Not compared” means ORION has not matched this wording against a complete set of SEC filings for its period. It says nothing either way about whether a matching filing exists. Wording without exact dates is not given calendar dates.
Historical summaries and source dates are retained separately from the SEC timing quotes above. Earlier publications were collected retrospectively.
Historical catalog checked .
No historical announcement trail is retained for this company in this catalog.
Original ClinicalTrials.gov record · Open the selected study
These are selected linked records and dated source metadata, not a live registry recheck or the company’s full pipeline. Company announcements and the selected registry study are separate evidence sets. No stage or event timing is borrowed between them.
Coverage and identity checksSuggest an SEC timing statement to add for RXRX. You can include the original filing link in your note. The founder reads each request by hand.
Or email ORION.
See RXRX in the calendar · Review labels and methodology